CTMX FY 2018 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M-16.9% YoY

Gross Profit

$60M100.0% margin

Operating Income

-$78M-130.9% margin

Net Income

-$85M-142.2% margin

EPS (Diluted)

$-2.03

Cash Flow

Operating Cash Flow

-$76M

Free Cash Flow

-$79M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$457M

Total Liabilities

$326M

Stockholders' Equity

$131M

Cash & Equivalents

$248M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$72M	-16.9%
Gross Profit	$60M	$72M	-16.9%
Operating Income	-$78M	-$46M	-68.3%
Net Income	-$85M	-$43M	-96.3%